Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

The DISCOVER INOCA Prospective Multi-center Registry

NCT05288361 · View on ClinicalTrials.gov ↗

Study Summary

The overall objective of this multi-center registry is to identify specific phenotypes of INOCA with both an anatomic evaluation (coronary angiography and intravascular imaging) and physiologic assessment with the Abbott Coroventis Coroflow Cardiovascular System, and to determine long-term outcomes.

Interventions

  • DIAGNOSTIC_TEST Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire

Study Locations (9)

New York

  • New York Presbyterian-Brooklyn Methodist Hospital — Brooklyn
  • NYU Langone Health — New York
  • Columbia University Irving Medical Center — New York

California

  • UCLA Health — Los Angeles
  • Stanford Hospital — Stanford

Connecticut

  • Yale New Haven Hospital — New Haven

Georgia

  • Northeast Georgia Medical Center — Gainesville

Ohio

  • The Christ Hospital — Cincinnati

Pennsylvania

  • Thomas Jefferson University Hospital — Philadelphia

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2022-09-14
Est. Completion 2032-12-31

Sponsor

Yale University

1,283 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05288361

The ClinicalTrials.gov registry entry for NCT05288361 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,283 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 6 conditions, with Endothelial Dysfunction appearing as the primary indexed condition, and to 1 intervention — of which Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05288361 reports 9 study locations spanning 6 distinct geographic areas — top geographies include New York, California, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05288361 about?

NCT05288361 is a clinical study titled "The DISCOVER INOCA Prospective Multi-center Registry". The overall objective of this multi-center registry is to identify specific phenotypes of INOCA with both an anatomic evaluation (coronary angiography and intravascular imaging) and physiologic assessment with the Abbott Coroventis Coroflow Cardiovascular System, and to determine long-term outcomes.

What is the current status of trial NCT05288361?

This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2022-09-14. Estimated completion is 2032-12-31.

What conditions does trial NCT05288361 study?

This clinical trial studies the following conditions: Endothelial Dysfunction, Coronary Microvascular Dysfunction, Microvascular Angina, Ischemia and No Obstructive Coronary Artery Disease, Coronary Vasospasm. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05288361?

The interventions under investigation include: Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05288361?

This trial is sponsored by Yale University, which has 1,283 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05288361 being conducted?

This trial has 9 study locations across California, Connecticut, Georgia, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial